Our AI-based approach is designed to:
- Enhance R&D efficiencies
- Shorten development timelines
- Increase probability of success
![](/wp-content/uploads/2024/06/ai_approach_6_21_v2.webp)
Oct 15, 2024
BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress DisorderVIEW RELEASE
Sep 19, 2024
BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for AgitationVIEW RELEASE
Sep 05, 2024
BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaVIEW RELEASE
Stock Information
BioXcel Therapeutics, Inc.
Oct 15, 2024 04:00 PM
MARKET/SYMBOL
Nasdaq:
BTAI
PRICE
0.5689
CHANGE
0.0325 (6.06%)